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MYELOMAWITH AL AMYLOIDOSIS: 10 YEARS EXPERIENCEWITH STEM
CELL TRANSPLANT
Silva, L.1, Weber, D.1, Wang, M.2, Han, E.2, Mendoza, F.2, de
Lima, M.1, Qazilbash, M.1, Champlin, R.E.1, Giralt, S.1 1The Univer-
sity of Texas MD Anderson Cancer Center, Houston, TX; 2The Univer-
sity of Texas MD Anderson Cancer Center, Houston, TX.
Background: (AL) Amyloidosis is a rare and potentially fatal dis-
ease that involves deposition of light chain protein by a clonal
plasma cell population. Treatment with high dose melphalan and
autologous stem cell transplant (ASCT) can improve survival and
reverse organ damage, but this treatment is associated with toxicity
and mortality. We reviewed the outcome of patients with amyloid-
osis, who received hematopoietic stem cell transplant (HSCT) at
our institution.Patients andMethods:The retrospective study an-
alyzed 32 patients with AL Amyloidosis who underwent transplant
between 1997–2006. There were 17 men and 15 women, with a me-
dium age of 53 years (range 35–73 years). All patients had diagnostic
criteria for multiple myeloma (MM) and had biopsy confirmed am-
yloidosis of at least one organ site. Six patients had at least 1 organ
involved with AL amyloidosis (3 bone marrows, 2 subcutaneous and
1 kidney), 20 patients had 2 organs involved, while 6 patients had 3
or more organs affected. Twenty-eight patients underwent autolo-
gous transplant, while 4 had an allogeneic transplants (2 syngeneic
and 2 siblings). The preparative regimens received in 28 patients
were high dose melphalan (26 autologous and 2 syngeneic), 2 pa-
tients received Busulfan and Melphalan, 2 allogeneic transplant Flu-
darabine and Melphalan. Results: The median Charlson
Comorbidities Index (CCI) was 3 (range 0–8). The median number
of CD341 cells infused was 4.85  106 cells/kg (range 1.43–7.82
cells/kg). The median time to neutrophil and platelet engraftment
were 11 (range 2–21 days) and 14 days (range 2–41), respectively.
56% of patients developed moderate to severe gastrointestinal ef-
fects. Four patients underwent allogeneic transplant and 1 had acute
and chronic graft vs host disease (GVHD). Twenty-one patients
(65%) achieved a partial hematological remission (PR), and 5 pa-
tients (15%) achieved complete hematological remission (CR),
with a total response hematological rate of 80%. The 100 day
NRM was 3.2%. The median overall survival was (OS) 41 months
(range 1–108), 7 patients died (4 relapsed and 3 infections) all 7 pa-
tients had CCI greater or equal to 4. Conclusion: Selected patients
with MM and amyloidosis can benefit from high dose therapy with
stem cell support including allogeneic transplantation. The high
mortality seen in patients with CCI .4 suggests that this index
could be useful in selecting patients for high dose chemotherapy.92
LONGTERM FOLLOW-UP OF PATIENTS WITH SYSTEMIC AL AMYLOID-
OSIS TREATED WITH HIGH-DOSE MELPHALAN AFTER INDUCTION
AND MOBILIZATION CHEMOTHERAPY
Schonland, S.O., Bochtler, T., Hansberg, M., Mangatter, A., Perz, J.B.,
Hundemer, M., Ho, A.D., Goldschmidt, H., Hegenbart, U. University of
Heidelberg, Heidelberg, Germany.
Introduction: Longterm survival in AL amyloidosis (AL) pa-
tients (pts) without evidence of disease has been shown recently after
high-dose melphalan (HDM) (Sanchorawala, Blood 2007). How-
ever, no advantage of HDM compared to conventional chemother-
apy has been observed in a randomized multicenter trial (Jaccard,
NEJM 2007). This was probably due to high transplantation related
mortality (TRM) and a substantially longer time to the start of che-
motherapy in the HDM group. Whether treatment intensification
using induction and mobilization chemotherapy prior HDM can
improve results is not well investigated. Methods: We have up-
dated 23 pts with AL (Perz, BJH 2004) who received vincristine/
adriamycine/dexamethasone as induction and mobilization chemo-
therapy prior to HDM in our center from 1998 until 2004. Inclu-
sion criteria were age\ 70 years, NYHA stage\ III and a WHO
performance status\ 3. Median age was 57 years; median number
of involved organs was 3. Thirteen pts had symptomatic organ in-
volvement of heart and kidney, respectively (on dialysis at HDM,
n 5 4). The median follow-up after HDM is 66 months. Results:TRM was 9%. Prior HDM 14% of pts achieved a complete remis-
sion (CR). CR rate increased to 67% post HDM and organ response
(OR) was observed in 57%. The median overall survival (OS) has
not been reached. Pts with CR have an estimated OS of 90% after
6 years; for pts not reaching CR the median OS is 48 months (p
5 0.002). Hematological relapse occurred in 50%; 6 pts are still
in first CR with an OR. Discussion: We observed a very high CR
and OR rate using this intensive treatment approach. Pts with CR
have an excellent survival. Therefore, the role of induction therapy
in AL should be further investigated in randomized trials in experi-
enced centers. Results might be also improved incorporating new
drugs in induction and consolidation therapies. The main goal of
treatment in AL remains achievement and maintenance of a CR
of the underlying plasma cell disorder.93
AUTOLOGOUS HEMATOPOIETIC TRANSPLANTATION FOLLOWING
HIGH-DOSE AND SUPRALETHAL CHEMORADIOTHERAPY USING
STORED NONCRYOPRESERVED AUTOLOGOUS PERIPHERAL BLOOD IN
COLOMBIA
Cuervo-Sierra, J.1,2, Guzman-Zapata, A.1,2, Quevedo-Velez, A.1,2, Du-
que-Martelo, J.I.1,2, Mondragon, M.C.2, Cuellar-Ambrosi, F.1,2 1Hospi-
tal Universitario San Vicente de Paul, Medellın, Colombia; 2School of
Medicine-Universidad deAntioquia, Medellın, Colombia.
Although cryopreservation is the standard for autotransplanta-
tion, it has logistic and financial disadvantages in undeveloped
countries such as Colombia.
Between September 1993 and August 2007, in 72 patients, pe-
ripheral blood was refrigerated at 4C up to 144 hours before
autotransplantation. 41 men and 31 women of median age 37 years
affected with High-risk or relapsing non-Hodgkin lymphoma
(NHL) (n 5 27, 37.5%), multiple mieloma (MM) (n 5 21,
29.16%), relapsing Hodgkin disease (n 5 12, 16.6%), acute leuke-
mias (n 5 8, 11.1%), Langerhans cell histiocytosis (n 5 2, 2.8%),
breast cancer (n 5 1, 1.4%) and autoimmune disease (n 5 1,
1.4%) were mobilized with G-CSF only. Conditioning regimens
were: MEL 200 in 21 patients, CBV in 28 patients, Cy-TBI in 13
patients, BEAM/BEAC in 7 patients, Fludarabine-MEL-Alemtuzu-
mab in 3 patients.
The 17 patients in Group 1 showed pre-refrigeration CFU-GM
of 2.62  105/kg (range 0.36 to 16.6  105/kg) and at re-infusion
1.36  105/kg (range 0 to 6.32  105/kg) of 83% viability (range,
78% to 96%). These patients showed . 0.5  109/L granulocytes
on day 1 11 (range, 9 to 15) and .20  109/L platelets on day
116 (range, 11 to 44). The 49 patients in Group 2 showed CD34
of 5.4  106/kg (range, 0.16 to 17.1  106/kg) and mononuclear
cell count (MNC) of 8.7  108/kg, reaching .0.5  10 9/L granu-
locytes at day113 (range, 9 to 17) and.20 109/L platelets on day
115 (range, 10 to 40). Among the 6 patients in Group 3, the average
of MNC of 10.73  108/kg was reached and .0.5  109/L granu-
locytes on day 111 (range, 10 to 16) and .20  109/L platelets on
day114 (range, 10 to 18). No graft failure was observed. No differ-
ences were observed between the groups. At three and five years
51% are alive in complete remission.
Refrigeration of peripheral blood is a simple, effective, and inex-
pensive method that can be considered for autotransplants within
a few days of harvesting where resources are limited for long-term
storage.94
DELAYED PLATELET ENGRAFTMENT AND OUTCOME OF STEM CELL
TRANSPLANT FOR MULTIPLE MYELOMA: POSSIBLE MICROENVIRON-
MENT EFFECT?
Kumar, S., Dispenzieri, A., Lacy, M.Q., Hayman, S.R., Buadi, F.K.,
Dingli, D., Rajkumar, S.V., Litzow, M.R., Gertz, M.A. Mayo Clinic,
Rochester, MN.
Background: Autologous stem cell transplantation (ASCT) is
an effective treatment modality for patients (pts) with multiple
Poster Session I 37myeloma (MM). While most of the pts relapse after ASCT with
a median time to progression (TTP) of 2 years, there is a significant
heterogeneity in the duration of response. It has been hypothesized
that the effect of high dose alkylator therapy used for conditioning
may have a dual effect on the MMcells as well as marrow microen-
vironment. It is also known that hematopoiesis, especially thrombo-
poiesis, depends to some extent on signals form the marrow
microenvironment. We examined if there was any relationship be-
tween delayed platelet engraftment and outcome after ASCT.
Methods: We examined the outcomes in a group of pts undergoing
ASCT for MM at our institution to compare the response duration
to platelet engraftment kinetics. We studied 687 pts undergoing
ASCT with melphalan conditioning followed by PB stem cells. Re-
sults: Among the 687 pts undergoing ASCT, 200 (29%) achieved
a platelet count of 50,000 by day 21 (early group) and the rest
achieved this level after 21 days or never engrafted (late group).
The TTP) among the late group was 24.8 mos (95% CI; 19.6, 30)
vs. 16.8 mos (95% CI; 15.1, 18.6) for the late group (p\ 0.001).
Pts in the late engraftment group were more likely to achieve a com-
plete response compared to the early group; 39% vs. 30%, p5 0.02.
In a multivariate analysis examining factors predicting for longer
TTP after ASCT, delayed platelet engraftment was independent
of ASCT within 12 months of diagnosis, CR with ASCT, absence
of cytogenetic abnormalities, B2M\3.5 mg/L and a plasma cell la-
beling index\1% at the time of ASCT.Conclusions: In this study,
we have demonstrated for the first time a relationship between de-
layed platelet engraftment after ASCT and the duration of response
following ASCT. This intriguing finding raises several hypotheses.
It is possible that the delayed platelet engraftment is a marker of
marrow microenvironment dysfunction secondary to high dose
therapy, given the role of marrow microenvironment on thrombo-
poiesis. It is possible that this is a surrogate marker for the biological
effectiveness of the melphalan dose, which can affect the other cells
in the marrow microenvironment as well. It is likely a reflection of
the marrow microenvironment dependence on the myeloma cells
for its survival. These findings should be confirmed in other larger
patient groups.95
NEULASTA AS GROWTH FACTOR SUPPORT AFTER AUTOLOGOUS
STEM CELL TRANSPLANTATION
Rice, R.D.1, Baker, L.B.2,Moskowitz, C.H.3 1Memorial Sloan-Kettering
Cancer Center, New York, NY; 2Memorial Sloan-Kettering Cancer Cen-
ter, New York, NY; 3Memorial Sloan-Kettering Cancer Center, New
York, NY.
Significance and Background: High-dose therapy and autolo-
gous stem cell transplant (HDT/SCT) is complicated by an ex-
pected period of pancytopenia, through which the patient must be
supported. With the introduction of granulocyte colony stimulating
factors in the early 1990s, this period was shortened. Still, pro-
longed neutropenia puts the patient at risk of infection which may
have serious consequences and may be fatal. Pegfilgrastim, a pegy-
lated version of filgrastim, has been used as post-HDT/SCT growth
factor support in a small number of European centers, but its use in
the United States for this indication has not been widely adopted.
Purpose: To evaluate the use of Neulasta (pegfilgrastim) as
post-transplant colony stimulating factor support compared to
Neupogen (filgrastim) for adult autologous SCT patients. Inter-
ventions: Between February and September 2007, we treated 56
patients who were undergoing HDT/SCT as standard of care
with pegfilgrastim 6 mg subcutaneously once on day 1 1. Patient
and treatment characteristics are detailed in the table below. We
compared this sample to an historical control sample of 190 patients
in 2005 who were treated with filgrastim (flat weight-based dosing)
starting on either day1 5 or day 1 1 and continuing until engraft-
ment. Evaluation: Mean day to neutrophil engraftment . 500 K/
mcL for the pegfilgrastim sample was 9.6 days (median 9 days),
compared to the historical control sample (mean 10.49 days; median
10 days). Average Wholesale Price (AWP) is not dramatically differ-
ent ($3,557 for Neulasta  1; $3090 for Neupogen 480 mcg  7
daily doses). One patient had a slow ANC engraftment (day 1
22). No patient had a delayed hospital discharge due to red bloodcell or platelet transfusion requirements. One patient had a pro-
tracted hospital course due to infectious complications; two patients
required transfer to the intensive care unit, one for sepsis, one for
infection and myocardial infarction. There were no observations
of clinically significant post-engraftment fevers or engraftment syn-
drome. Treatment related mortality in this cohort was 0%.Discus-
sion: Neulasta is equally efficacious in neutrophil recovery as
Neupogen post autologous HDT/SCT. It has the advantage of re-
quiring only one injection for the patient and appears to potentiate
a reduction in overall hospital length of stay.Patient/Treatment CharacteristicsGender
Male 33
Female 23Median Age 55
Diagnosis
Diffuse Large B Cell
Lymphoma8Mantle Cell
Lymphoma8Peripheral T Cell
Lymphoma3Hodgkin Lymphoma 6
Multiple myeloma 27
AL Amyloidosis 4Conditioning
BEAM 18
CBV 4
MELPHALAN 31
TBI/CY/ETOP 396
INCIDENCE AND FACTORS INFLUENCING STEM CELL MOBILIZATION IN
PATIENTS WITH NON-HODGKIN’S LYMPHOMA (NHL) AND HODGKIN’S
DISEASE (HD)
Popat, U., Saliba, R., Ahlawat, S., Okoroji, G.-J., Alousi, A.,
Anderlini, P., Andersson, B., de Lima, M., Jones, R., Kebriaei, P.,
Korbling, M., Nieto, Y., Qazilbash, M., Shpall, E.J., Khouri, I.,
Giralt, S., Champlin, R., Hosing, C. University of Texas M.D. Anderson
Cancer Center, Houston, TX.
Background: Autologous transplantation from peripheral blood
stem cells is an important curative therapeutic option in patients
with chemosensitive Hodgkin’s (HD) and non-Hodgkin’s Lym-
phoma (NHL), but is not available for patients who fail to mobilize.
In this study we wished to estimate the incidence of mobilization
failure in lymphoma patients seen at M.D. Anderson Cancer Center
and identify predictive factors. Methods: We retrospectively re-
viewed charts of all patients referred in the calendar years 2003
and 2004 with NHL and HD, in whom peripheral blood stem
cell collection was attempted. Mobilization failure was defined as
inability to collect 2  106 CD341 cells/Kg. Predictors of mobili-
zation failure were evaluated using logistic regression analysis in-
cluding type of mobilization chemotherapy, age, sex, number of
prior chemotherapies, bone marrow cellularity, platelet count,
white blood cell count, prior bone marrow involvement with malig-
nancy, and prior radiation. Results: During the study period, 206
patients, 130 males and 76 females with a median age of 48 years
(range 10–81 years) were deemed eligible for autologous transplant
and underwent stem cell mobilization. Sixty five patients had HD
and 141 patients had NHL. Mobilization regimens were as follows:
Ifosfamide and Etoposide 147, Cyclophosphamide 14, other che-
motherapeutic regimens 26, and G-CSF alone 19. Twenty-nine
of 206 (14%) patients failed to mobilize stem cells. The majority
of these cases (26/29) were NHL patients (odds ratio for NHL ver-
sus HD: 4.7; p5 0.01). On univariate analysis, use of G-CSF alone
as opposed to chemotherapy, platelet count\150K/ul, and bone
marrow cellularity\ 30% were the only significant predictors of
mobilization failure in NHL. In view of small number of patients
multivariate analysis was not possible. However, a low platelet
